CABALETTA BIO INC (CABA) Fundamental Analysis & Valuation

NASDAQ:CABA • US12674W1099

Current stock price

2.9498 USD
-0.1 (-3.29%)
Last:

This CABA fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

0

1. CABA Profitability Analysis

1.1 Basic Checks

  • In the past year CABA has reported negative net income.
  • In the past year CABA has reported a negative cash flow from operations.
  • In the past 5 years CABA always reported negative net income.
  • In the past 5 years CABA always reported negative operating cash flow.
CABA Yearly Net Income VS EBIT VS OCF VS FCFCABA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 2025 -50M -100M -150M

1.2 Ratios

  • CABA's Return On Assets of -101.68% is on the low side compared to the rest of the industry. CABA is outperformed by 76.74% of its industry peers.
  • The Return On Equity of CABA (-149.80%) is worse than 63.95% of its industry peers.
Industry RankSector Rank
ROA -101.68%
ROE -149.8%
ROIC N/A
ROA(3y)-63.66%
ROA(5y)-54.58%
ROE(3y)-84.84%
ROE(5y)-68.89%
ROIC(3y)N/A
ROIC(5y)N/A
CABA Yearly ROA, ROE, ROICCABA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 50 -50 100 -100

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for CABA so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CABA Yearly Profit, Operating, Gross MarginsCABA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024 2025

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

3

2. CABA Health Analysis

2.1 Basic Checks

  • Compared to 1 year ago, CABA has more shares outstanding
  • Compared to 5 years ago, CABA has more shares outstanding
  • Compared to 1 year ago, CABA has a worse debt to assets ratio.
CABA Yearly Shares OutstandingCABA Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M 100M
CABA Yearly Total Debt VS Total AssetsCABA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M 200M 250M

2.2 Solvency

  • Based on the Altman-Z score of -3.33, we must say that CABA is in the distress zone and has some risk of bankruptcy.
  • CABA has a Altman-Z score of -3.33. This is comparable to the rest of the industry: CABA outperforms 43.99% of its industry peers.
  • CABA has a Debt/Equity ratio of 0.03. This is a healthy value indicating a solid balance between debt and equity.
  • The Debt to Equity ratio of CABA (0.03) is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity 0.03
Debt/FCF N/A
Altman-Z -3.33
ROIC/WACCN/A
WACCN/A
CABA Yearly LT Debt VS Equity VS FCFCABA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 100M -100M 200M

2.3 Liquidity

  • CABA has a Current Ratio of 2.77. This indicates that CABA is financially healthy and has no problem in meeting its short term obligations.
  • CABA has a worse Current ratio (2.77) than 66.09% of its industry peers.
  • A Quick Ratio of 2.77 indicates that CABA has no problem at all paying its short term obligations.
  • CABA's Quick ratio of 2.77 is on the low side compared to the rest of the industry. CABA is outperformed by 63.76% of its industry peers.
Industry RankSector Rank
Current Ratio 2.77
Quick Ratio 2.77
CABA Yearly Current Assets VS Current LiabilitesCABA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M 200M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. CABA Growth Analysis

3.1 Past

  • CABA shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 2.56%.
EPS 1Y (TTM)2.56%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%38.46%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • Based on estimates for the next years, CABA will show a quite strong growth in Earnings Per Share. The EPS will grow by 19.89% on average per year.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y29.95%
EPS Next 2Y14.85%
EPS Next 3Y10.05%
EPS Next 5Y19.89%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
CABA Yearly Revenue VS EstimatesCABA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2027 2028 2029 2030 2031 2032 2033 500M 1B 1.5B
CABA Yearly EPS VS EstimatesCABA Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 2 -2 4 -4 6

More info and screens

Find the best growth stocksShow best growing peers

0

4. CABA Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for CABA. In the last year negative earnings were reported.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CABA. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CABA Price Earnings VS Forward Price EarningsCABA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CABA Per share dataCABA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 -2

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y14.85%
EPS Next 3Y10.05%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. CABA Dividend Analysis

5.1 Amount

  • CABA does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

CABA Fundamentals: All Metrics, Ratios and Statistics

CABALETTA BIO INC

NASDAQ:CABA (4/24/2026, 12:04:31 PM)

2.9498

-0.1 (-3.29%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-23
Earnings (Next)05-13
Inst Owners68.51%
Inst Owner Change-0.04%
Ins Owners1.45%
Ins Owner Change8.39%
Market Cap328.37M
Revenue(TTM)N/A
Net Income(TTM)-167.86M
Analysts83.75
Price Target13.39 (353.93%)
Short Float %18.2%
Short Ratio8.25
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)12.12%
Min EPS beat(2)8.61%
Max EPS beat(2)15.63%
EPS beat(4)2
Avg EPS beat(4)1.93%
Min EPS beat(4)-10.16%
Max EPS beat(4)15.63%
EPS beat(8)2
Avg EPS beat(8)-0.08%
EPS beat(12)5
Avg EPS beat(12)1.72%
EPS beat(16)8
Avg EPS beat(16)4.19%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)4.32%
EPS NQ rev (3m)4.32%
EPS NY rev (1m)11.77%
EPS NY rev (3m)12.37%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 2.93
P/tB 2.93
EV/EBITDA N/A
EPS(TTM)-2.28
EYN/A
EPS(NY)-1.6
Fwd EYN/A
FCF(TTM)-1.19
FCFYN/A
OCF(TTM)-1.18
OCFYN/A
SpS0
BVpS1.01
TBVpS1.01
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0 (-100%)
Profitability
Industry RankSector Rank
ROA -101.68%
ROE -149.8%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-63.66%
ROA(5y)-54.58%
ROE(3y)-84.84%
ROE(5y)-68.89%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.03
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 74.67%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.77
Quick Ratio 2.77
Altman-Z -3.33
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)56.26%
Cap/Depr(5y)107.34%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)2.56%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%38.46%
EPS Next Y29.95%
EPS Next 2Y14.85%
EPS Next 3Y10.05%
EPS Next 5Y19.89%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-37.32%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-5.64%
EBIT Next 3Y-9.45%
EBIT Next 5YN/A
FCF growth 1Y-46.31%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-48.58%
OCF growth 3YN/A
OCF growth 5YN/A

CABALETTA BIO INC / CABA Fundamental Analysis FAQ

What is the ChartMill fundamental rating of CABALETTA BIO INC (CABA) stock?

ChartMill assigns a fundamental rating of 1 / 10 to CABA.


What is the valuation status for CABA stock?

ChartMill assigns a valuation rating of 0 / 10 to CABALETTA BIO INC (CABA). This can be considered as Overvalued.


Can you provide the profitability details for CABALETTA BIO INC?

CABALETTA BIO INC (CABA) has a profitability rating of 0 / 10.


How financially healthy is CABALETTA BIO INC?

The financial health rating of CABALETTA BIO INC (CABA) is 3 / 10.